Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E. Karr, . . . Steven G. Gourlay. (2022). Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Wiley.
Chicago Style (17th ed.) CitationTimothy D. Owens, et al. Phase 1 Clinical Trial Evaluating Safety, Exposure and Pharmacodynamics of BTK Inhibitor Tolebrutinib (PRN2246, SAR442168). Wiley, 2022.
MLA (9th ed.) CitationTimothy D. Owens, et al. Phase 1 Clinical Trial Evaluating Safety, Exposure and Pharmacodynamics of BTK Inhibitor Tolebrutinib (PRN2246, SAR442168). Wiley, 2022.
Warning: These citations may not always be 100% accurate.